Compare ALOY & HELP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALOY | HELP |
|---|---|---|
| Founded | 2024 | N/A |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 862.3M | 889.9M |
| IPO Year | 2021 | 2020 |
| Metric | ALOY | HELP |
|---|---|---|
| Price | $8.17 | $12.73 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $35.00 | ★ $51.50 |
| AVG Volume (30 Days) | ★ 1.7M | 1.7M |
| Earning Date | 06-17-2026 | 07-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $692,803.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.83 | $3.76 |
| 52 Week High | $26.90 | $15.15 |
| Indicator | ALOY | HELP |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 52.90 |
| Support Level | $7.89 | $11.68 |
| Resistance Level | $9.42 | $14.75 |
| Average True Range (ATR) | 0.49 | 0.96 |
| MACD | 0.02 | -0.19 |
| Stochastic Oscillator | 15.44 | 25.33 |
REalloys Inc is a development-stage company building a North American integrated rare earth to high-performance neodymium iron boron (NdFeB) magnet materials and magnet supply chain focused on meeting the demands of the protected markets of the United States, which includes the U.S. National Defense Stockpiles (NDS), Defense Industrial Base (DIB), Nuclear Industrial Base (NIB), robotics, electric aviation, and critical infrastructure industries. The company operates in a single, integrated rare-earth development and supply chain enterprise focused on building a North American mine-to-magnet supply chain for U.S. Protected Markets.
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.